Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Shares Issued (2016 - 2024)

Fate Therapeutics (FATE) has disclosed Shares Issued for 11 consecutive years, with $74.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Shares Issued rose 28113.58% year-over-year to $74.2 million, compared with a TTM value of $74.2 million through Sep 2025, up 247353.33%, and an annual FY2024 reading of $74.5 million, changed N/A over the prior year.
  • Shares Issued was $74.2 million for Q4 2024 at Fate Therapeutics, up from -$74.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $74.2 million in Q4 2024 and bottomed at -$74.2 million in Q3 2024.
  • Average Shares Issued over 5 years is $8.5 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Shares Issued crashed 117.47% in 2023, then soared 93925.86% in 2024.
  • Year by year, Shares Issued stood at -$40.3 million in 2020, then soared by 100.08% to $34000.0 in 2021, then skyrocketed by 4361.76% to $1.5 million in 2022, then plummeted by 117.47% to -$265000.0 in 2023, then skyrocketed by 28113.58% to $74.2 million in 2024.
  • Business Quant data shows Shares Issued for FATE at $74.2 million in Q4 2024, -$74.2 million in Q3 2024, and $54.5 million in Q2 2024.